Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Dosage Forms × CNS × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Lymphoid 4 Gastrointestinal 4 Genitourinary 3 Other solid neoplasm 2 Other 1 Myeloid 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neurofibromatosis 1 1

Interventions

Temozolomide 527 Radiotherapy 347 Bevacizumab 217 Magnetic Resonance Spectroscopy 191 Radiosurgery 146 Cyclophosphamide 146 Carboplatin 133 Etoposide 109 Radiation 106 Irinotecan 97 Vincristine 90 Cisplatin 81 Filgrastim 80 pembrolizumab 76 Specimen Handling 75 Nivolumab 72 Lomustine 72 Surgical Procedures, Operative 68 Topotecan 57 Melphalan 50 Carmustine 49 Radiotherapy, Intensity-Modulated 48 Granulocyte Colony-Stimulating Factor 45 Doxorubicin 45 sargramostim 44 Peripheral Blood Stem Cell Transplantation 43 Blood Specimen Collection 43 Chemotherapy, Adjuvant 42 Isotretinoin 41 Erlotinib Hydrochloride 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡